Dual antiplatelet therapy is critical to inhibit platelet reactivity in order to prevent ischemic recurrences in stented patients. However, studies have observed a variable blockade of the P2Y12 adenosine diphosphate receptor between patients following clopidogrel intake. This interindividual variability in the biological response is not uncommon with clopidogrel (about 50%) and even prasugrel (20%). High on-treatment platelet reactivity (HTPR) is correlated with thrombotic events following percutaneous coronary intervention. Several studies suggested that tailoring of antiplatelet therapy based on platelet reactivity (PR) monitoring could safely reduce the rate of major adverse cardiovascular events in HTPR patients. In addition, low on-treatment PR was recently associated with bleeding events both in patients treated with prasugrel and clopidogrel. Of importance, bleedings are associated with a poor prognosis in stented patients. Overall, the potential of PR monitoring to individualize antiplatelet therapy might benefit stented patients by reducing both ischemic and bleeding risks. However, such strategies remain to be evaluated in adequately designed large-scale randomized clinical trials.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1586/14779072.2013.820440 | DOI Listing |
Dermatitis
December 2024
From the Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. This study aimed to identify predictive factors for early and late responders to tralokinumab treatment.
View Article and Find Full Text PDFEnviron Epidemiol
February 2025
Department of Epidemiology and Biostatistics, University of Nevada Las Vegas, School of Public Health, Las Vegas, Nevada.
Background: Toxicological studies suggest neonicotinoids increase oxidative stress and inflammation, but few epidemiological studies have explored these effects.
Methods: National Health and Nutrition Examination Survey (NHANES) 2015-2016 data were used to estimate associations between neonicotinoid exposure and inflammatory markers, including the C-reactive protein-to-lymphocyte count ratio (CLR), monocyte-to-high-density lipoprotein ratio (MHR), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) using linear and multinomial logistic regression models. Sex was evaluated as a potential modifier.
Medeni Med J
December 2024
Health Sciences University Türkiye, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Clinic of Gastroenterology, Ankara, Türkiye.
Objective: In this study, the aim was to evaluate the diagnostic effectiveness of more easily applicable and cost-effective serum biomarkers, such as neutrophil-to-lymphocyte ratio (NLR), platelet-tolymphocyte ratio (PLR), C-reactive protein (CRP) to albumin ratio (CAR), and CRP-to-lymphocyte ratio (CLR), instead of the endoscopic activity index (EAI) used to determine disease activation in ulcerative colitis (UC) patients.
Methods: Blood tests performed during the same period as colonoscopy were reviewed, and NLR, PLR, CAR, and CLR values were calculated. Based on the EAI score, patients with a score <4 were classified as having UC in remission, those with a score ≥4 as having active UC, and those with normal colonoscopy results as the control group.
Eur J Surg Oncol
December 2024
Critical Care Division, University Hospital 'Virgen Del Rocío', Avda Manuel Siurot S/n, 41013, Seville, Spain. Electronic address:
Background: One-third of patients with peritoneal carcinomatosis undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) present alterations in conventional coagulation test results. However, perioperative coagulation has not been systematically investigated in these patients. This study aimed to investigate hemostatic changes in such patients.
View Article and Find Full Text PDFBMC Rheumatol
December 2024
Molecular Medicine Research Center, Khomein University of Medical Sciences, Khomein, Iran.
Background: Reducing inflammation is central to the management of RA. However, commonly used markers such as CRP and ESR, along with the DAS-28 score, have shown limitations. Hematologic indices, such as platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and neutrophil-lymphocyte ratio (NLR), show potential as reliable indicators of inflammation in RA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!